HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025. Beginning with the opening of trading on August 18, 2025, Salarius’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X503.
Related Questions
How will the 1-for-15 reverse split affect the stock’s liquidity and daily trading volume?
What is the expected post‑split share price and how will the market capitalization change?
Will the reverse split affect the company’s eligibility for inclusion in any Nasdaq or other indices?
How might the split influence the pricing and availability of options and other derivatives on SLRX?
What are the potential regulatory or compliance implications associated with the reverse split?
Is the market perceiving the reverse split as a signal of financial distress or a strategic move to improve share perception?
What effect will the split have on key valuation metrics such as EPS, P/E, and price‑to‑sales ratios?
How will the reduction in share count impact the float and potential short‑interest dynamics?
How does this reverse split compare to recent similar actions by peer biopharma companies?
Could the split impact the company’s ability to raise capital in future financing rounds?